Bioinformatic Analysis Identifies Three Potentially Key Differentially Expressed Genes in Peripheral Blood Mononuclear Cells of Patients with Takayasu’s Arteritis

Renping Huang, M.D.1, Yang He, M.M.2, Bei Sun, M.D.3, Bing Liu, M.M.*1
1. Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China
2. Department of Anesthesiology, The First Affiliated Hospital of Harbin Medical University, Harbin, China
3. Department of Pancreatic and Biliary Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China

*Corresponding Address: Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, No.199, Dazhi Street, Nangang District, Harbin, 150001, China
Email: liubing2016lb@hotmail.com

Received: 29/Dec/2016, Accepted: 9/May/2017

Abstract
Objective: This study aimed to identify several potentially key genes associated with the pathogenesis of Takayasu's arteritis (TA). This identification may lead to a deeper mechanistic understanding of TA etiology and pave the way for potential therapeutic approaches.

Materials and Methods: In this experimental study, the microarray dataset GSE33910, which includes expression data for peripheral blood mononuclear cell (PBMC) samples isolated from TA patients and normal volunteers, was downloaded from the publicly accessible Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified in PBMCs of TA patients compared with normal controls. Gene ontology (GO) enrichment analysis of DEGs and analysis of protein-protein interaction (PPI) network were carried out. Several hub proteins were extracted from the PPI network based on node degrees and random walk algorithm. Additionally, transcription factors (TFs) were predicted and the corresponding regulatory network was constructed.

Results: A total of 932 DEGs (372 up- and 560 down-regulated genes) were identified in PBMCs from TA patients. Interestingly, up-regulated and down-regulated genes were involved in different GO terms and pathways. A PPI network of proteins encoded by DEGs was constructed and RHOA, FOS, EGR1, and GNB1 were considered to be hub proteins with both higher random walk score and node degree. A total of 13 TFs were predicted to be differentially expressed. A total of 49 DEGs had been reported to be associated with TA in the Comparative Toxicogenomics Database (CTD). The only TA marker gene in the CTD database was NOS2, confirmed by three studies. However, NOS2 was not significantly altered in the analyzed microarray dataset. Nevertheless, NOS3 was a significantly down-regulated gene and was involved in the platelet activation pathway.

Conclusion: RHOA, FOS, and EGR1 are potential candidate genes for the diagnosis and therapy of TA.

Keywords: Candidate Gene, Peripheral Blood Mononuclear Cell, Protein-Protein Interaction Network, Takayasu’s Arteritis

Citation: Huang R, He Y, Sun B, Liu B. Bioinformatic analysis identifies three potentially key differentially expressed genes in peripheral blood mononuclear cells of patients with takayasu's arteritis. Cell J. 2018; 19(4): 647-653. doi: 10.22074/cellj.2018.4991.

Introduction

Takayasu’s arteritis (TA), also known as aortoarteritis and pulseless disease, is a rare chronic large vessel vasculitis of unknown etiology, affecting large arteries, especially the aorta and its main branches and the pulmonary artery (1). TA can lead to progressive occlusion, stenosis or aneurismal transformation (2). It usually affects young women under 40 years of age and is associated with important morbidity and mortality, particularly if there is a diagnostic delay (3). Therefore, gaining more insight into the underlying mechanism of TA is of great significance.

Clinically, TA includes an early phase with nonspecific systemic signs and symptoms of fever, arthralgia, night sweats, headaches, weight loss and myalgia (4). As vessel inflammation progresses, clinical features of this disease become apparent due to wall thickening, fibrosis, stenosis and thrombus formation (5). Tripathy et al. (6) investigated the expression of different cytokines at the transcript level in peripheral blood mononuclear cells (PBMCs) of patients with TA and demonstrated an inflammatory cytokine signature in TA with key roles suggested for tumor necrosis factor (TNF)-α, interleukin (IL)-4, and IL-10 in different pathological processes of this disorder. In addition, Soto et al. (7) identified the presence of IS6110 and HupB gene sequences associated with Mycobacterium tuberculosis in aortic tissues of TA patients. Recently, a study identified a novel susceptibility locus in the IL12B region for TA which could be potentially used as a genetic marker for the severity of this disease (8). However, data on genes associated with TA are very limited. The identification of key genes associated with this disorder may provide insight into the pathogenesis underlying TA and provide novel avenues for therapeutic intervention in TA.

Okuzaki et al. (9) used high-density oligonucleotide microarrays to identify genes expressed in PBMCs of TA patients regardless of symptoms and demonstrated that Ficolin 1 (FCN1) expression was elevated in peripheral blood samples of TA patients. In this study, we downloaded and reanalyzed this microarray dataset and differentially expressed genes (DEGs) were identified in PBMCs of TA patients compared with normal controls. Gene ontology (GO) enrichment analysis of DEGs and analysis of their interactions in the protein-protein interaction (PPI) network were carried out. Several hub proteins were extracted from
the PPI network based on node degree and random walk algorithm. Additionally, transcription factors (TFs) were predicted and the regulatory network was constructed. We sought to identify several potentially key genes associated with the pathogenesis of TA, which may lead to a deeper mechanistic understanding of TA and potential therapeutic approaches.

Materials and Methods

In this experimental study, the gene expression dataset GSE33910 deposited by Okuzaki et al. (9) was downloaded from the publicly accessible Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/) (10). Expression data were generated on a GPL4133 Agilent-014850 Whole Human Genome Microarray 4x44K G4112F. A total of 8 two-color arrays were included and each individual array comprised a target sample (Cy5-labeled) and a control sample (Cy3-labeled). The target samples were derived from PBMCs isolated from eight TA patients who were diagnosed as TA. All RNA samples isolated from the PBMCs of 17 healthy normal volunteers were included as control samples.

Data preprocessing and screening of differentially expressed genes

The raw data in TXT format were downloaded. The two-color array data was preprocessed by using the Bioconductor limma package (11), including background correction, normalization and expression value calculation (12). Subsequently, by using the limma package (11), we identified DEGs between TA samples and control samples. The P values of an unpaired Student’s t test (13) with the matrix of gene expression values as the response variable was used to evaluate significance of differential expression. The Benjamini-corrected false discovery rate (FDR) (14) was applied to correct the raw P values for multiple testing. To get a reliable list of significant DEGs, the results were concurrently filtered using a cutoff of log2 FC (fold change) and FDR-corrected P values. The selection of a specific threshold in this study was based on the usefulness of the data at hand and the results obtained for the follow-up analyses. Thus, cutoff points for up- and down-regulated genes in this study were |log2 FC| ≥ 1.5 and FDR < 0.05.

Functional and pathway enrichment analysis

To interpret biological function of the DEGs, we performed an enrichment analysis in terms of GO and the Kyoto encyclopedia of genes and genomes (KEGG) pathways. GO term and KEGG pathway analyses were carried out with the web-based tool DAVID bioinformatics resources (version 6.8) (15). The selection of a cut-off criterion for GO and pathway enrichment analysis was based on the number of observed GO terms or pathways. In this study, P < 0.05 (by hypergeometric test) were used as an empirical threshold for retrieving altered pathways or GO terms with gene count ≥ 2.

Construction of protein-protein interaction network and extraction of significant nodes

The STRING database (http://string-db.org) provides a critical integration of PPIs, including known and predicted interactions. The interaction evidence could be examined by adjusting the interaction confidence scores, which is a key feature of STRING (16). Furthermore, each interaction in the STRING database is annotated with benchmarked confidence scores (low confidence: scores < 0.4, medium: 0.4 to 0.7, high: > 0.7) (17). In this study, a PPI network of proteins encoded by DEGs was constructed using the STRING database. The PPI score was set at 0.7 (high confidence). Additionally, network visualization was performed with the Cytoscape software (18). Nodes in the PPI network represented proteins and the interaction between any two nodes is represented by an edge. The random walk algorithm on the network is an iterative walker’s transition from a given seed node (protein) to a randomly selected neighbor based on the structure of the network (19). In each step, the walker has a probability of returning to the initial nodes. Finally, each node (protein) in the random walk process can be assigned with a transition probability which is proportional to the frequency of the interactions between the seed proteins and other proteins (19, 20). Genes with higher random walk score were considered to be significant nodes in the network.

In this study, we employed a random walk algorithm for the genes in the PPI network to prioritize significant genes using the R package RWOAG (https://r-forge.r-project.org/R/?group_id=1126) (19). Additionally, significant genes were also identified by degree centrality.

Transcription factor prediction and construction of the regulatory network

iRegulon, a Cytoscape plugin, implements a genome-wide ranking-and-recovery approach and relies on the analysis of the regulatory sequences flanking each gene to detect enriched TF motifs and their optimal direct target subsets (21). We therefore used the iRegulon plugin (21) to identify TFs potentially regulating the DEGs and those of which were differentially expressed. The parameters were set at minimum identity between orthologous genes: 0.05 and maximum FDR on motif similarity: 0.001. The normalized enrichment score (NES)>3 was considered as a cut-off for the selection of the predicted TFs and their targets. The threshold value for differentially expressed TFs was |log2 FC| ≥ 0.5 and P < 0.05, which is less stringent than that for DEG screening.

Takayasu’s arteritis-associated gene prediction

The comparative toxicogenomics database (CTD, http://ctdbase.org/) is a public resource that provides information on connections between environmental chemicals or drugs and gene products, and their relationships to different disorders (22). This database was used to identify DEGs that have been reported to be associated with TA in the literature.

Results

Differentially expressed genes identification and functional enrichment analysis

The expression profile of TA pathogenesis was explored by identifying DEGs in PBMC samples of TA patients compared with normal controls. Of the total of 19, 215 genes analyzed on the microarray, 932 genes were differentially expressed of which 372 were up-regulated and 560 were down-regulated. To investigate which cellular functions were affected by these DEGs, GO terms and pathway enrichment analysis was conducted. The top five over-represented GO terms
under three cellular categories [biological process (BP), cellular component (CC), and molecular function (MF)] and the main enriched pathways are shown in Table 1. Interestingly, we found that the up-regulated genes and the down-regulated genes were involved in different GO terms and pathways.

| Expression change | Category | Term                                                      | Count | P value    |
|-------------------|----------|-----------------------------------------------------------|-------|------------|
| Up                | BP       | GO:0010467~gene expression                               | 40    | 1.23E-05   |
|                   |          | GO:0060968~regulation of gene silencing                  | 5     | 4.30E-05   |
|                   |          | GO:0007596~blood coagulation                             | 23    | 2.99E-04   |
|                   |          | GO:0038061~NIK/NF-kappaB signaling                       | 8     | 3.33E-04   |
|                   |          | GO:0006521~regulation of cellular amino acid metabolic process | 7     | 4.66E-04   |
|                   | CC       | GO:0070062~extracellular exosome                         | 105   | 3.38E-12   |
|                   |          | GO:0005829~cytosol                                      | 97    | 3.81E-06   |
|                   |          | GO:0005654~nucleoplasm                                  | 76    | 1.16E-04   |
|                   |          | GO:0005839~proteasome core complex                       | 5     | 4.22E-04   |
|                   |          | GO:0000502~proteasome complex                            | 7     | 9.47E-04   |
|                   | MF       | GO:0005515~protein binding                              | 206   | 7.95E-05   |
|                   |          | GO:0004298~threonine-type endopeptidase activity         | 5     | 6.73E-04   |
|                   |          | GO:0044822~poly(A) RNA binding                           | 35    | 7.68E-03   |
|                   |          | GO:0005102~receptor binding                             | 14    | 1.98E-02   |
|                   |          | GO:0003924~GTPase activity                              | 10    | 3.03E-02   |
|                   | PATHWAY  | hsa03050:Proteasome                                    | 7     | 4.85E-04   |
|                   |          | hsa05133:Pertussis                                     | 7     | 7.67E-03   |
|                   |          | hsa05034:Alcoholism                                     | 10    | 2.17E-02   |
|                   |          | hsa00760:Nicotinate and nicotinamide metabolism         | 4     | 2.89E-02   |
|                   |          | hsa00240:Pyrimidine metabolism                          | 7     | 3.49E-02   |
|                   |          | hsa05322:Systemic lupus erythematosus                   | 8     | 3.60E-02   |
| Down              | BP       | GO:0006415~translational termination                     | 11    | 4.15E-05   |
|                   |          | GO:0016259~selenocysteine metabolic process             | 11    | 5.60E-05   |
|                   |          | GO:0001887~selenium compound metabolic process          | 12    | 1.01E-04   |
|                   |          | GO:0006414~translational elongation                     | 11    | 1.29E-04   |
|                   |          | GO:0006614~SRP-dependent cotranslational protein targeting to membrane | 11    | 2.89E-04   |
|                   | CC       | GO:0001533~cornified envelope                            | 7     | 8.47E-04   |
|                   |          | GO:0030141~secretory granule                            | 8     | 2.37E-03   |
|                   |          | GO:0022627~cytosolic small ribosomal subunit             | 6     | 3.11E-03   |
|                   |          | GO:0022625~cytosolic large ribosomal subunit            | 6     | 1.45E-02   |
|                   |          | GO:0005615~extracellular space                          | 42    | 4.72E-02   |
|                   | MF       | GO:0003735~structural constituent of ribosome           | 13    | 3.94E-03   |
|                   |          | GO:0043565~sequence-specific DNA binding                | 18    | 1.37E-02   |
|                   |          | GO:0005179~hormone activity                             | 7     | 2.39E-02   |
|                   |          | GO:0005198~structural molecule activity                | 11    | 3.34E-02   |
|                   |          | GO:0005201~extracellular matrix structural constituent  | 5     | 3.50E-02   |
|                   | PATHWAY  | hsa03010:Ribosome                                       | 13    | 6.69E-05   |
|                   |          | hsa04080:Neuroactive ligand-receptor interaction         | 14    | 1.32E-02   |
|                   |          | hsa04721:Synaptic vesicle cycle                         | 6     | 1.59E-02   |
|                   |          | hsa04724:Glutamatergic synapse                          | 8     | 1.76E-02   |
|                   |          | hsa04010:MAPK signaling pathway                         | 12    | 3.66E-02   |

Go; Gene ontology, DEGs; Differentially expressed genes, BP; Biological process, CC; Cellular component, and MF; Molecular function. P values were calculated by the hypergeometric test.
Protein-protein interaction network construction and prediction of significant genes

The PPI network consisted of 627 interactions (edges) among 330 proteins (nodes) (Fig.1). The top 15 DEGs in the network ranked by the random walk score and top DEGs ranked by degree are shown (Table 2). The top four genes in the network based on random walk score and node degree were Ras homolog family member A (RHOA, up-regulated), FBJ murine osteosarcoma viral oncogene homolog (FOS, up-regulated), early growth response 1 (EGR1, down-regulated), and G protein subunit beta 1 (GNB1, up-regulated). On the other hand, nitric oxide synthase 3 (NOS3, down-regulated) ranked 6 based on the random walk score, while the node degree of NOS3 was 11. Besides, a number of RPL family members were with a higher node degree but were not in the top 15 nodes ranked by the random walk score. These results suggested that there was little difference in the list of significant genes in the PPI network identified by the random walk algorithm with that based on node degree. In addition, we performed pathway enrichment analysis on the top 15 DEGs. The results showed that these DEGs were predominantly involved in 4 pathways, namely hsa05133:pertussis, hsa04921:oxytocin signaling pathway, hsa04611:platelet activation, and hsa04062:chemokine signaling pathway. Interestingly, RHOA, NOS3, and LYN Proto-Oncogene, Src Family Tyrosine Kinase (LYN) were involved in platelet activation, a TA-associated pathway.

Table 2: The top 15 DEGs ranked by the random walk score and their degree

| Node   | Random walk score | Node            | Degree |
|--------|-------------------|-----------------|--------|
| RHOA   | 0.0084665         | GNB1            | 27     |
| FOS    | 0.0078574         | FOS             | 26     |
| EGR1   | 0.0074923         | RHOA            | 23     |
| GNB1   | 0.0062084         | EGR1            | 19     |
| NOS3   | 0.00601           | RPL38, RPS9, RPS29 | 15   |
| UQCRCl | 0.0058351         | RPS12, FPR2, RPL32, RPL19 | 14 |
| MYOD1  | 0.0054857         | HSPB1, MRPL24, RPL35A, RPS21 | 13 |
| HSPB1  | 0.0052129         | OXT, RPS4Y2, RPS4Y1, RPLP2, RPL36A | 12 |
| NOTCH1 | 0.0048462         | NOS3, SNRPD2, F2RL1, EIF3I | 11 |
| LYN    | 0.0047398         | MYOD1, NOTCH1, GHSR | 10 |
| IRF1   | 0.004669          | RAP1A, SRSF2, PRPF6, CCR5, XCR1, HCRT | 9  |
| ITGAM  | 0.0044762         | UQCRCl, LYN, ITGAM, NUP153, PSMD6, PSMA7, CMPK1, CSTF1, FUS, SF3A2, U2AF2, TACR2, KISS1R | 8  |
| EPRS   | 0.004437          | IRF1, EPRS, UBE2I, CD4, CSK, NOP58, PSMB3, DDX23, GALR3, GRM2, C3AR1, NPBRW1, OPRD1 | 7  |
| STX4   | 0.0042952         | H2AFZ, YARS, TI4M1, IL1B, LMNB1, NOC4L, PDE6D, TUFM, ENTPD1, MMP14, PSMB6 | 6  |
| OXT    | 0.0042259         | FURIN, CCT3, HIST1H3A, TIMP1, B3GNT7, HIST1H2AC, HIST1H2AD, H2AFB2, CD79A, NGF, MRPL17, GALNT1, MUC3A, MUC6, C1GALT1C1, NTSC, NTSM, OASL, IISG15, EGR3, ITPA, PSMB8, OR4C46, OR8D1, OR2C1, OR6Y1, OR10H2, NLE1, PSME4, CD3G | 5  |
Transcriptional regulation network analysis and prediction of Takayasu’s arteritis-associated genes

A total of 13 TFs were predicted to be differentially expressed (Table 3), such as the YY1 Transcription Factor (YY1) and the Fli-1 Proto-Oncogene, ETS Transcription Factor (FLI1). The transcriptional regulatory network was constructed (Fig.2). Based on the CTD database, a total of 893 genes had curated or inferred association with TA of which 49 were identified to be DEGs in this study (Table 4). The only TA marker gene in the CTD database was NOS2, confirmed by three studies (23-25). However, NOS2 was not significantly altered in the analyzed microarray dataset. Nevertheless, NOS3 was a significantly down-regulated gene and was also a hub in the PPI network.

Table 3: Expression profile of predicted TFs

| TF    | Log FC | P value | adj.P.val |
|-------|--------|---------|-----------|
| POU2F2| 1.322403| 2.06E-02| 0.081647  |
| ETS2  | 1.322031| 2.15E-02| 0.078272  |
| YY1   | 1.264822| 1.11E-03| 0.019872  |
| FLI1  | 1.22772 | 4.01E-03| 0.034229  |
| TOX2  | 1.062465| 1.08E-03| 0.021665  |
| E2F2  | 1.052923| 9.83E-03| 0.04705   |
| E2F1  | 0.96085 | 3.17E-03| 0.031772  |
| KLF13 | 0.71519 | 3.47E-02| 0.108853  |
| ETS1  | 0.563542| 2.51E-02| 0.072435  |
| POU3F3| -0.96573| 1.39E-02| 0.063961  |
| POU2AF1| -0.96704| 9.49E-03| 0.051347  |
| ELF5  | -1.0965 | 1.42E-02| 0.05923   |
| PAX4  | -2.0087 | 3.69E-02| 0.101316  |

TF; Transcription factor.

Discussion

In the present study, by integrating the expression profile of TA patients, we identified three potentially key genes in TA, namely RHOA, FOS, and EGR1. RHOA encodes a member of the Rho family of small GTPases and functions as a molecular switch in signal transduction cascades (26). Ample evidence has demonstrated that RHOA is required for transendothelial migration, a tightly regulated process whereby leukocytes migrate from the vasculature into tissues (27-29). Transendothelial migration of leukocytes to the sites of inflammation is a critical step in the inflammatory response (29). Moreover, TA is a chronic disease characterized by inflammation of large vessels (30). In this study, RHOA was not only a hub protein in the PPI network, but it also was upregulated. These results suggest that RHOA may play a key role in the pathogenesis of TA. Experimental validation will be needed to confirm this finding.

FOS was also found to be a hub in the PPI network of DEGs. FOS encodes a leucine zipper protein which can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1 (31). AP-1 can in
turn be phosphorylated and regulated by mitogen-activated protein kinases (MAPKs) in response to Toll-like receptor (TLR) signaling stimuli (32). Additionally, a study has shown that TLR ligands can function as instigators of vessel wall inflammation in giant cell arteritis, another type of large vessel vasculitis (33). Overall, our results are consistent with the accumulating evidence implicating FOS in the pathogenesis of TA through the TLR signaling pathway.

The third hub based on both higher random walk score and node degree was EGR1. The protein encoded by EGR1 belongs to the EGR family of C2H2-type zinc-finger proteins. It is a nuclear protein and functions as a transcriptional regulator (36). Decker et al. (35) showed that EGR-1 could regulate IL-2 transcription by a synergistic interaction with the nuclear factor of activated T cells. In addition, Tripathy et al. (36) demonstrated that high TNF-α and low IL-2-producing T cells played an important role in TA. This is consistent with the observation of EGR-1 being a down-regulated hub. Thus, we suggest that down-regulation of EGR-1 in PBMCs of TA patients may be pathogenically significant. However, further investigations are needed to validate this association.

We conclude that the several putative genes identified here, in particular RHOA, FOS and EGR1, may play key roles in the pathogenesis of TA and could become potential targets for future therapeutic strategies. The limitation of this analysis was the small sample size in this study and lack of experimental validation. Further studies with larger sample size concerning these genes may confirm the hitherto unknown mechanism underlying the pathogenesis of TA. This in turn may expand the therapeutic arsenal against TA.

Acknowledgments

This work was financially supported by China Postdoctoral Science Foundation funded project (No.2017M611384), the research subject grant of Health and Family Planning Commission of Heilongjiang Province (No. 2016-004). The Authors declares that there is no conflict of interest.

Author’s Contributions

R.H., Y.H.; Carried out the conception and design of the research, Y.H., B.S.; Participated in the acquisition of data. B.L., Y.H.; Carried out the analysis and interpretation of data. R.H., B.L.; Conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

References

1. Clement M, Galy A, Bruneval P, Morvan M, Hyafil F, Benali K, et al. Tertiary lymphoid organs in takayasu arteritis. Frontiers Immunol. 2016; 7: 158.
2. Hassani M. Takayasu arteritis associated with severe renovascular hypertension. Saudi journal of kidney diseases and transplantation: an official publication of the saudi center for organ transplantation. Saudi Arabia. 2016; 27(2): 402-406.
3. Tombetti E, Di CM, Sartorelli S, Bozzolo E, Sabbadini MG, Manfredi AA, et al. Anti-cytokine treatment for takayasu arteritis: state of the art. Intractable Rare Dis Res. 2014; 3(1): 521-546.
4. Andrews J, Mason JC. Takayasu’s arteritis—recent advances in imaging offer promise. Rheumatology (Oxford). 2007; 46(1): 6-15.
5. Maffei S, Di Renzo M, Bova G, Auteri A, Pasqui AL. Takayasu’s arteritis: a review of the literature. Intern Emerg Med. 2006; 1(2): 105-112.
6. Tripathy NK, Chauhan SK, Nityanand S. Cytokine mRNA repertoire of peripheral blood mononuclear cells in Takayasu’s arteritis. Clin Exp Immunol. 2004; 138(2): 369-374.
7. Soto ME, Del Carrion Avila-Casado M, Huercas-Gomez C, Alarcon GV, Castrojen V, Soto V, et al. Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic wall tissue of patients with Takayasu’s arteritis. BMC Infectious Diseases. 2012; 12: 194.
8. Matsumura T, Amiya E, Tamura N, Maejima Y, Komuro I, Isobe M. A novel susceptibility locus for Takayasu arteritis in the IL12B region can be a genetic marker of disease severity. Heart Vessels. 2016; 31(6): 1016-1019.
9. Okuzaki D, Kobayashi S, Sakurai K, Tongiga K, Okamoto A, Matsunaga T, et al. Polymorphism of IL10 gene is elevated in the peripheral blood mononuclear cells of takayasu’s vasculitis patients. J Mol Biomark Diagn. 2012; 3(3): 125-131.
10. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashovsky M, et al. NCBI GEO: archive for functional genomics data sets—update 2014. Nucleic Acids Res. 2014; 41(Database issue): D911-D915.
11. Ritchie ME, Pepison B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015; 43(7): e47.
12. Oshlack A, Chabolet AE, Smyth GK, Gilad Y. Using DNA microarrays to study gene expression in closely related species. Bioinformatics. 2007; 23(10): 1235-1242.
13. Baldi P, Long AD. A bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics. 2001; 17(6): 509-519.
14. Pawitan Y, Michiels S, Koscielny S, Sargent D, Peneau A, Ploner A, False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics. 2005; 21(13): 3017-3024.
15. Huang DW, Sherman BT, Tan Q, Kir J, Liu D, Bryant D, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res. 2007; 35(Web Server issue): W169-175.
16. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013; 41(Database issue): D808-D815.
17. Von Mering C, Jensen LJ, Snel B, Hooper SD, Krupp M, Fuggerliemi M, et al. STRING: known and predicted protein-protein associations, integrated and transferred across organisms. Nucleic Acids Res. 2005; 33(Database issue): D433-D437.
18. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011; 27(3): 431-432.
19. Kohler S, Bauer S, Horn D, Robinson P. Walking the interactome for prioritization of candidate disease genes. American Journal of Human Genetics. 2008; 82(4): 949-958.
20. Erten S, Bebek G, Koyutürk M, Vavien: an algorithm for prioritizing candidate disease genes. Human Genetics. 2008; 120(3): 25. Uyama O, Nagatsuka K, Nakamura M, Matsumoto M, Fujisawa A, Yoneda S, et al. Plasma concentrations of 6-keto-prostaglandin F1
alpha in patients with hypertension, cerebrovascular disease or Takayasu’s arteritis. Thrombosis Research. 1982; 25(1-2): 71-79.

26. Wagner E, Glotzer M. Local RhoA activation induces cytokinetic furrows independent of spindle position and cell cycle stage. J Cell Biol. 2016; 213(6): 641-649.

27. Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol. 2001; 154(1): 147-160.

28. Heasman SJ, Carlin LM, Cox S, Ng T, Ridley AJ. Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol. 2010; 190(4): 553-563.

29. Schimmel L, Heemskerk N, van Buul JD. Leukocyte transendothelial migration: a local affair. Small GTPases. 2016; 1-15.

30. Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis. Arthritis Rheumatol. 2015; 67(5): 1353-1360.

31. Uluckan O, Guinea-Viniegra J, Jimenez M, Wagner EF. Signalling in inflammatory skin disease by AP-1 (Fos/Jun). Clin Exp Rheumatol. 2015; 33(4 Suppl 92): S44-S49.

32. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine. 2010; 49(1): 1-9.

33. Ma-Krupa W, Kwan M, Goronzy JJ, Weyand CM. Toll-like receptors in giant cell arteritis. Clin Immunol. 2005; 115(1): 38-46.

34. Feng Y, Desjardins CA, Cooper O, Kontor A, Nocco SE, Naya FJ. Correction: EGR1 functions as a potent repressor of MEF2 transcriptional activity. PLoS One. 2015; 10(6): e0131619.

35. Decker EL, Skerka C, Zipfel PF. The early growth response protein (EGR-1) regulates interleukin-2 transcription by synergistic interaction with the nuclear factor of activated T cells. J Biol Chem. 1998; 273(41): 26923-26930.

36. Tripathy NK, Gupta PC, Nityanand S. High TNF-alpha and low IL-2 producing T cells characterize active disease in Takayasu’s arteritis. Clin Immunol. 2006; 118(2-3): 154-158.